Trial Profile
A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2020
Price :
$35
*
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 23 Sep 2019 Primary endpoint (Change from baseline in the Modified Unified Parkinsons Disease Rating Scale (MDS UPDRS) Score Part III at week 15, evaluating motor symptoms: tavapadon compared with placebo) has been met, according to a Cerevel Therapeutics media release.
- 23 Sep 2019 According to a Cerevel Therapeutics media release, results of this study are being presented today at the 2019 International Congress of Parkinsons Disease and Movement Disorders (Nice, France) by David Gray, Ph.D., vice president of chemistry at Cerevel Therapeutics and this study team leader, during a poster presentation session.
- 23 Sep 2019 Results presented in a Cerevel Therapeutics media release.